New TIPS Study Shows IV Iron is Safe, Effective, and Well-Tolerated for Pregnant Women

Miami, FL -- Jan 13th, 2025 -- FEM Women's Health (formerly known as Heme On Call) and GNP Research today announced results from the TIPS Study, the largest real-world evaluation of IV iron treatment in pregnant women in the United States. The findings--now presented at the American Society of Hematology (ASH) 67th Annual Meeting 2025, the leading global hematology conference -- show that IV iron is safe, effective, and fast-acting treatment option for pregnant women with low iron levels or anemia.

The study followed 2,225 pregnant women who received IV iron in community clinics. Treated for iron deficiency or iron deficiency anemia (IDA), conditions that often cause fatigue, shortness of breath, and odd cravings during pregnancy. Across nearly 5,000 IV iron infusions, the research showed that IV iron is well-tolerated and provides rapid improvement in symptoms and blood counts.
What the Study Found
o Fewer total visits are required with high-dose IV iron, improving treatment completion and patient convenience

o Fewer discomfort symptoms with high-dose formulations, particularly Monoferric (ferric derisomaltose) (7.8%) and Feraheme (ferumoxytol) (15.2%), compared with Venofer (iron sucrose) (22.2%)

o Serious reactions were rare, occurring in only 3.3% of all infusions

o More than 80% of women reported feeling better, including more energy, reduced shortness of breath, and fewer cravings like ice chewing

o Women with anemia saw an average of +1.2-point ride in hemoglobin

"These findings show that when iron deficiency is recognized and treated promptly, IV iron provides fast, reliable improvement in maternal well-being without compromising safety" said Dr. Steven Fein, CEO of FEM Women's Health.
Why This Matters for Pregnancy
Iron deficiency during pregnancy is common, yet many women remain under-treated or treated too late to prevent symptoms that affect daily functioning and delivery readiness. The TIPS Study shows that IV iron offers a safe, rapid, and well-tolerated option for restoring iron levels and improving quality of life during pregnancy.

In practice, TIPS support a shift towards earlier diagnosis and timely IV iron therapy, improving maternal well-being with a low-risk, high-benefit therapy. For busy expectant mothers, quick and reliable treatment can make a meaningful difference in day-to-day well-being and overall pregnancy health.

Disclosure: This study was conducted with independent research grant support from Pharmacosmos Therapeutics Inc.
Media Contact:
Anthony Persaud

Director, Corporate Development FEM Women's Health

o hematoloy@femwomenshealth.com

1-888-403-7640

femsurvivorship.com
ABOUT FEM WOMEN'S HEALTH
FEM Women's Health is a leading women's tele-hematology and infusion center network specializing in iron deficiency, anemia, and cancer survivorship care. Through evidence based IV iron therapies and coordinated virtual access to hematology experts, FEM supports patients from diagnosis through treatment and recovery. With a continuously expanding network of infusion centers across Florida, FEM is committed to delivering accessible, high-quality care that improves outcomes and empowers women to thrive with better health.
ABOUT GNP RESEARCH
GNP Research is an independent health outcomes research organization dedicated to generating real-world evidence that strengthens community-based clinical care. GNP partners with medical practices nationwide to evaluate treatment, safety, and effectiveness. GNP Research supports providers in advancing the standard of care and delivering measurable improvements in patient outcomes.

Contact Details

Organization: Fem Womens Health

Contact Person: Anthony Persaud

Website: https://www.femwomenshealth.com/

Email: Send Email [https://dashboard.kingnewswire.com/release-contact/40129]

Country: United States

Release Id: 13012640129

The post New TIPS Study Shows IV Iron is Safe, Effective, and Well-Tolerated for Pregnant Women appeared first on King Newswire. This content is provided by a third-party source. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the 'Media Contact' section above.

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. king Newswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact support@kingnewswire.com

This release was published on openPR.